Table 1.
Effectiveness of semaglutide versus control in HbA1c and weight reduction
| Study | Duration (weeks) | Route | Dose (mg) | Comparator | HbA1c (%) Reduction |
Weight (kg) Reduction |
|---|---|---|---|---|---|---|
| SUSTAIN 125 | 30 | subcutaneous | 0.5 1.0 |
Placebo | −1.43* −1.53* |
−2.75* −3.56* |
| SUSTAIN 227 | 56 | subcutaneous | 0.5 1.0 |
Sitagliptin 100 mg | −0.77* −1.06* |
−2.35* −4.2* |
| SUSTAIN 328 | 56 | subcutaneous | 1.0 | Exanatide ER | −0.62* | −3.78* |
| SUSTAIN 429 | 30 | subcutaneous | 0.5 1.0 (+insulin) |
Glargine U100 | −0.38* −0.81* |
−4.62* −6.33* |
| SUSTAIN 531 | 30 | subcutaneous | 0.5 1.0 (+insulin) |
Placebo | −1.35* −1.75* |
−2.31* −5.06* |
| SUSTAIN 626 | 104 | subcutaneous | 0.5 1.0 |
Placebo | −0.7* −1.0* |
−2.9* −4.3* |
| SUSTAIN 730 | 40 | subcutaneous | 0.5 1.0 |
Delaglutide: 0.75 1.5 |
−0.4* −0.41* |
−2.26* −3.55* |
| Davies et al10 | 26 | Per Os | 2.5 5.0 10.0 20.0 40.0 |
Placebo | −0.4* −0.9* −1.2* −1.4* −1.6* |
−0.9 –1.5 –3.6* −5.0* −5.7* |
Notes: *P<0.01.
Abbreviations: SUSTAIN, semaglutide unabated sustainability in treatment of type 2 diabetes; s.c, subcutaneous; p.os, per os; HbA1c, glycated haemoglobin A1c.